Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: A modeling study

Global Heart

Volumn 9, Issue 4, 2014, Pages 391-398.e3

  Megiddo, Itamar ^a   Chatterjee, Susmita ^b   Nandi, Arindam ^a,b   Laxminarayan, Ramanan ^a,b  

^a Economics and Policy   (United States)

^b PUBLIC HEALTH FOUNDATION OF INDIA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STREPTOKINASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG USE; FRAMINGHAM RISK SCORE; GROSS NATIONAL PRODUCT; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INDIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; POPULATION DISTRIBUTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYPHARMACOLOGY; THEORETICAL MODEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYOCARDIAL INFARCTION; POLYPHARMACOLOGY; SECONDARY PREVENTION;

EID: 84920839089     PISSN: 22118160     EISSN: 22118179     Source Type: Journal    
DOI: 10.1016/j.gheart.2014.07.002     Document Type: Article

References (28)

1. Gupta R. Burden of coronary heart disease in India. Indian Heart J 2005;57:632-8.
2. Institute for Health Metrics and Evaluation (IHME). GBD Database. Seattle, WA: IHME, University of Washington, 2014. Available at: http://ghdx.healthdata.org/global-burden-disease-study-2010-gbd-2010-datadownloads. Accessed November 13, 2013.
3. Government of India. Guidelines for the management of cardiovascular diseases in India. 2010. Available at: http://clinicalestablishments.nic.in/En/1068-standard-treatment-guidelines.aspx. Accessed October 20, 2013.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
5. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-86.
6. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005;112:3547-53.
7. Gaziano TA, Reddy KS, Paccaud F, Horton S. Cardiovascular disease. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington, DC: World Bank; 2006. p. 654-63.
8. Yusuf S, Islam S, Chow CK, et al., for the PURE Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43.
9. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009;6:101-10.
10. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-4.
11. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004;82:935-9.
12. Xavier D, Pais P, Devereaux PJ, et al., for the CREATE Registry Investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008;371:1435-42.
13. Yusuf S, Hawken S, Ounpuu S, et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
14. World Bank. Health nutrition and population statistics: population estimates and projections. Available from: http://databank.worldbank.org/Data/Views/VariableSelection/SelectVariables.aspx?source=Health%20Nutrition%20and%20Population%20Statistics:%20Population%20estimates%20and%20projections. Accessed September 11, 2014.
15. Prabhakaran D, Yusuf S, Mehta S, et al. Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart J 2005;57:217-25.
16. Riewpaiboon A. Standard cost lists for health technology assessment. J Med Assoc Thai 2014;97:S127-34.
17. Current Index of Medical Specialties India (CIMS). CIMS India. Available at: http://www.cimsasia.com/India/Browse/Alphabet/A?cat=drug&tab=Generic. Accessed October 10, 2013.
18. Mathers CD, Lopez AD, Murray CJ, et al. The burden of disease and mortality by condition: data, methods, and results for 2001. In: Lopez AD, Mathers CD, Ezzati M, et al., editors. Global Burden of Disease and Risk Factors. Washington, DC: World Bank; 2006. p. 45-93.
19. Yusuf S, Pais P, Afzal R, et al., for the TIPS Investigators. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-51.
20. Jeemon P, Prabhakaran D, Huffman MD, et al., for the Sentinel Surveillance in Industrial Populations Study Group. Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open 2011;1:e000068.
21. National Commission on Macroeconomics and Health. NCMH Background Papers - Burden of Disease in India. New Delhi, India: NCMH; 2005.
22. World Health Organization. WHO Guide to Cost-Effectiveness Analysis. Geneva, Switzerland: WHO; 2003.
23. Manoria PC, Manoria P, Manoria P, Parashar SK. The nuances of new antiplatelet drugs in acute coronary syndrome. J Indian Coll Cardiol 2013;3:16-23.
24. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 2014;129:2329-45.
25. Basu S, Babiarz K, Ebrahim S, Vellakkal S, Stuckler D, Goldhaber-Fiebert JD. Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ 2013;347:f6048.
26. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol 2006;111:189-94.
27. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007;297:286-94.
28. World Health Organization. Cardiovascular disease prevention and control: Translating evidence into action 2005:3-39. Available at: http://apps.who.int/iris/handle/10665/43235. Accessed December 12, 2013.